1-anilino-8-naphthalenesulfonate has been researched along with Arteriosclerosis, Coronary in 88 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the association between the variant M235T locus of angiotensinogen (AGT) gene, 584C/T locus of Endothelial lipase (EL) gene, and coronary artery disease (CAD) by meta-analysis." | 9.05 | Gene polymorphism associated with angiotensinogen (M235T), endothelial lipase (584C/T) and susceptibility to coronary artery disease: a meta-analysis. ( Hu, S; Rong, J; Zhao, H; Zhao, R, 2020) |
| " The relationship between phytosterols and coronary artery disease (CAD) is controversially discussed." | 5.22 | Genome-wide meta-analysis of phytosterols reveals five novel loci and a detrimental effect on coronary atherosclerosis. ( Baber, R; Ceglarek, U; Delgado, GE; Gieger, C; Gross, A; Gylling, H; Horn, K; Isermann, B; Kähönen, M; Kirsten, H; Kleber, ME; Kovacs, P; Lehtimäki, T; Loeffler, M; März, W; Meitinger, T; Mishra, PP; Müller-Nurasyid, M; Peters, A; Pott, J; Raitakari, O; Scholz, M; Stumvoll, M; Teupser, D; Thiery, J; Tönjes, A, 2022) |
| "To explore the association between the variant M235T locus of angiotensinogen (AGT) gene, 584C/T locus of Endothelial lipase (EL) gene, and coronary artery disease (CAD) by meta-analysis." | 5.05 | Gene polymorphism associated with angiotensinogen (M235T), endothelial lipase (584C/T) and susceptibility to coronary artery disease: a meta-analysis. ( Hu, S; Rong, J; Zhao, H; Zhao, R, 2020) |
| " The incidence of adverse events was similar between the placebo and MEDI5884 groups." | 3.01 | LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. ( Conway, J; Falloon, J; George, RT; Grimsby, J; Guan, Y; Hirshberg, B; Hsia, J; Hummer, BT; Karathanasis, SK; Koren, MJ; Kuder, JF; Murphy, SA; Rosenbaum, AI; Ruff, CT; Sabatine, MS; Tsai, LF; Tu, X, 2021) |
| "Epidemiological studies indicate that NAFLD raises risk of fatal or non-fatal CVD events." | 2.72 | Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. ( Corsini, A; Dongiovanni, P; Paolini, E; Ruscica, M; Sirtori, CR, 2021) |
| "First described in 1980, nonalcoholic fatty liver disease (NAFLD) has become more common although the exact incidence and prevalence is unknown." | 2.58 | NAFLD-NASH: An Under-Recognized Epidemic. ( Faselis, C; Jennings, J; Yao, MD, 2018) |
| "Patients with type 2 diabetes mellitus or the metabolic syndrome have a unique dyslipidemia characterized by hypertriglyceridemia; elevated blood levels of apolipoprotein B; small, dense low-density lipoprotein (LDL) cholesterol; and low levels of high-density lipoprotein (HDL) cholesterol, in particular HDL(2)-C." | 2.42 | Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. ( Ayyobi, AF; Brunzell, JD, 2003) |
| "Coronary artery disease is a multifactorial genetic disease caused by the interaction between genetic and environmental factors." | 1.62 | Association between ( Ahmadi, F; Bijanzadeh, M; Haghighizadeh, MH; Seyedian, SM, 2021) |
| "We demonstrated that in myocardium coronary atherosclerosis increases only the transcript level of G0S2 and FABP4." | 1.56 | The Gene and Protein Expression of the Main Components of the Lipolytic System in Human Myocardium and Heart Perivascular Adipose Tissue. Effect of Coronary Atherosclerosis. ( Chabowski, A; Gil, M; Górski, J; Hirnle, T; Knapp, M; Lewkowicz, J; Lisowska, A; Mikłosz, A; Wójcik, B, 2020) |
| "Carotid atheroma plaque samples were obtained from 31 diabetic and 48 non-diabetic patients undergoing carotid endarterectomy." | 1.43 | Specific enrichment of 2-arachidonoyl-lysophosphatidylcholine in carotid atheroma plaque from type 2 diabetic patients. ( Abello, N; Athias, A; Denimal, D; Ducoroy, P; Kretz, B; Lagrost, L; Martin, L; Masson, D; Ménégaut, L; Pais de Barros, JP; Petit, JM; Steinmetz, E; Truntzer, C, 2016) |
| "To evaluate coronary atherosclerosis, we used CSI (coronary stenosis index) calculated from coronary angiograms." | 1.33 | CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia. ( Higashikata, T; Inazu, A; Katsuda, S; Kawashiri, MA; Kobayashi, J; Mabuchi, H; Miwa, K; Nohara, A; Takata, M; Yamagishi, M, 2006) |
| "Homozygous familial hypercholesterolemia (FH) is a rare genetic disorder that leads to premature atherosclerosis due to a defective LDL receptor." | 1.30 | Lipoprotein lipase correlates positively and hepatic lipase inversely with calcific atherosclerosis in homozygous familial hypercholesterolemia. ( Brewer, HB; Dugi, KA; Feuerstein, IM; Hill, S; Hoeg, JM; Santamarina-Fojo, S; Shih, J, 1997) |
| "Triiodothyronine (T3) was significantly lower (P less than 0." | 1.27 | Progression and regression of human coronary atherosclerosis. The role of lipoproteins, lipases and thyroid hormones in coronary lesion growth. ( Arntzenius, AC; Barth, JD; Birkenhager, JC; Jansen, H; Kromhout, D; Reiber, JH, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (6.82) | 18.7374 |
| 1990's | 7 (7.95) | 18.2507 |
| 2000's | 37 (42.05) | 29.6817 |
| 2010's | 27 (30.68) | 24.3611 |
| 2020's | 11 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ruff, CT | 1 |
| Koren, MJ | 1 |
| Grimsby, J | 1 |
| Rosenbaum, AI | 1 |
| Tu, X | 1 |
| Karathanasis, SK | 1 |
| Falloon, J | 1 |
| Hsia, J | 1 |
| Guan, Y | 1 |
| Conway, J | 1 |
| Tsai, LF | 1 |
| Hummer, BT | 1 |
| Hirshberg, B | 1 |
| Kuder, JF | 1 |
| Murphy, SA | 1 |
| George, RT | 1 |
| Sabatine, MS | 1 |
| Scholz, M | 1 |
| Horn, K | 1 |
| Pott, J | 1 |
| Gross, A | 1 |
| Kleber, ME | 2 |
| Delgado, GE | 1 |
| Mishra, PP | 1 |
| Kirsten, H | 1 |
| Gieger, C | 1 |
| Müller-Nurasyid, M | 1 |
| Tönjes, A | 1 |
| Kovacs, P | 1 |
| Lehtimäki, T | 2 |
| Raitakari, O | 1 |
| Kähönen, M | 1 |
| Gylling, H | 1 |
| Baber, R | 1 |
| Isermann, B | 1 |
| Stumvoll, M | 1 |
| Loeffler, M | 1 |
| März, W | 2 |
| Meitinger, T | 1 |
| Peters, A | 1 |
| Thiery, J | 1 |
| Teupser, D | 1 |
| Ceglarek, U | 1 |
| Knapp, M | 2 |
| Łukaszuk, B | 1 |
| Lisowska, A | 2 |
| Hirnle, T | 2 |
| Górski, J | 2 |
| Chabowski, A | 2 |
| Mikłosz, A | 2 |
| Lewkowicz, J | 1 |
| Gil, M | 1 |
| Wójcik, B | 1 |
| Yang, J | 1 |
| Li, X | 1 |
| Xu, D | 1 |
| Zhao, H | 1 |
| Zhao, R | 1 |
| Hu, S | 1 |
| Rong, J | 1 |
| Wu, YE | 1 |
| Ma, L | 1 |
| Zhang, H | 1 |
| Chen, XR | 1 |
| Xu, XY | 1 |
| Hu, ZP | 1 |
| Park, HS | 1 |
| Kim, IJ | 1 |
| Kim, EG | 1 |
| Ryu, CS | 1 |
| Lee, JY | 1 |
| Ko, EJ | 1 |
| Park, HW | 1 |
| Sung, JH | 1 |
| Kim, NK | 1 |
| Dongiovanni, P | 1 |
| Paolini, E | 1 |
| Corsini, A | 1 |
| Sirtori, CR | 1 |
| Ruscica, M | 1 |
| Seyedian, SM | 1 |
| Bijanzadeh, M | 1 |
| Ahmadi, F | 1 |
| Haghighizadeh, MH | 1 |
| Abudureyimu, S | 1 |
| Abulaiti, P | 1 |
| Li, H | 1 |
| Xing, Z | 1 |
| Liu, S | 1 |
| Li, W | 1 |
| Gao, Y | 1 |
| Jennings, J | 1 |
| Faselis, C | 1 |
| Yao, MD | 1 |
| Muraba, Y | 1 |
| Koga, T | 1 |
| Shimomura, Y | 1 |
| Ito, Y | 1 |
| Hirao, Y | 1 |
| Kobayashi, J | 3 |
| Kimura, T | 2 |
| Nakajima, K | 2 |
| Murakami, M | 1 |
| Silbernagel, G | 1 |
| Scharnagl, H | 1 |
| Delgado, G | 1 |
| Stojakovic, T | 1 |
| Laaksonen, R | 1 |
| Erdmann, J | 1 |
| Rankinen, T | 1 |
| Bouchard, C | 1 |
| Landmesser, U | 2 |
| Schunkert, H | 1 |
| Grammer, TB | 1 |
| Elnaggar, IZ | 1 |
| Hussein, S | 1 |
| Amin, MI | 1 |
| Abdelaziz, EA | 1 |
| Verdier, C | 1 |
| Ruidavets, JB | 1 |
| Bongard, V | 1 |
| Taraszkiewicz, D | 1 |
| Martinez, LO | 1 |
| Elbaz, M | 1 |
| Ferrières, J | 1 |
| Perret, B | 1 |
| Ikeda, Y | 2 |
| Hirano, K | 2 |
| Fukushima, N | 1 |
| Sawa, Y | 1 |
| Sun, L | 1 |
| Ishida, T | 2 |
| Miyashita, K | 1 |
| Kinoshita, N | 1 |
| Mori, K | 1 |
| Yasuda, T | 1 |
| Toh, R | 1 |
| Imamura, S | 1 |
| Hirata, K | 2 |
| Guay, SP | 1 |
| Brisson, D | 1 |
| Lamarche, B | 1 |
| Gaudet, D | 1 |
| Bouchard, L | 1 |
| Cai, GJ | 1 |
| He, GP | 1 |
| Huang, ZY | 1 |
| Qi, CP | 1 |
| Kaneko, K | 1 |
| Kuroda, H | 1 |
| Izumi, R | 1 |
| Tateyama, M | 1 |
| Kato, M | 1 |
| Sugimura, K | 1 |
| Sakata, Y | 1 |
| Aoki, M | 1 |
| Xie, L | 1 |
| Sun, Y | 1 |
| Tong, Y | 1 |
| Liu, Y | 1 |
| Deng, Y | 1 |
| Ménégaut, L | 1 |
| Masson, D | 1 |
| Abello, N | 1 |
| Denimal, D | 1 |
| Truntzer, C | 1 |
| Ducoroy, P | 1 |
| Lagrost, L | 2 |
| Pais de Barros, JP | 1 |
| Athias, A | 1 |
| Petit, JM | 1 |
| Martin, L | 1 |
| Steinmetz, E | 1 |
| Kretz, B | 1 |
| Christiansen, MK | 1 |
| Jensen, JM | 1 |
| Brøndberg, AK | 1 |
| Bøtker, HE | 1 |
| Jensen, HK | 1 |
| Cai, G | 2 |
| Zhang, B | 2 |
| Shi, G | 2 |
| Weng, W | 2 |
| Yang, L | 2 |
| Xue, S | 2 |
| Ma, C | 1 |
| Posadas-Sánchez, R | 1 |
| López-Uribe, ÁR | 1 |
| Posadas-Romero, C | 1 |
| Pérez-Hernández, N | 1 |
| Rodríguez-Pérez, JM | 1 |
| Ocampo-Arcos, WA | 1 |
| Fragoso, JM | 1 |
| Cardoso-Saldaña, G | 1 |
| Vargas-Alarcón, G | 1 |
| Trbušić, M | 1 |
| Potočnjak, I | 1 |
| Tiran, B | 1 |
| Bodrožić-Džakić, T | 1 |
| Milošević, M | 1 |
| Degoricija, V | 1 |
| Frank, S | 1 |
| Simons, N | 1 |
| Isaacs, A | 1 |
| Koek, GH | 1 |
| Kuč, S | 1 |
| Schaper, NC | 1 |
| Brouwers, MCGJ | 1 |
| Ghatrehsamani, K | 1 |
| Darabi, M | 1 |
| Rahbani, M | 1 |
| Hashemzadeh Chaleshtory, M | 1 |
| Farrokhi, E | 1 |
| Noori, M | 1 |
| Strang, AC | 1 |
| Hovingh, GK | 3 |
| Stroes, ES | 1 |
| Kastelein, JJ | 6 |
| Vergeer, M | 1 |
| Cohn, DM | 1 |
| Boekholdt, SM | 2 |
| Sandhu, MS | 1 |
| Prins, HM | 1 |
| Ricketts, SL | 1 |
| Wareham, NJ | 1 |
| Khaw, KT | 1 |
| Kamphuisen, PW | 1 |
| Dallinga-Thie, GM | 2 |
| Fang, YQ | 2 |
| He, DF | 1 |
| Yang, CM | 1 |
| Wang, XK | 1 |
| Zeng, CY | 1 |
| Wang, HY | 1 |
| Fu, CJ | 1 |
| Shi, WB | 1 |
| Zhang, Y | 2 |
| Kimura, H | 2 |
| Miyazaki, R | 2 |
| Imura, T | 2 |
| Masunaga, S | 2 |
| Shimada, A | 1 |
| Mikami, D | 1 |
| Kasuno, K | 1 |
| Takahashi, N | 1 |
| Hirano, T | 1 |
| Yoshida, H | 2 |
| Ramakrishnan, L | 1 |
| Sachdev, HS | 1 |
| Sharma, M | 1 |
| Abraham, R | 1 |
| Prakash, S | 1 |
| Gupta, D | 1 |
| Singh, Y | 1 |
| Bhaskar, S | 1 |
| Sinha, S | 1 |
| Chandak, GR | 1 |
| Reddy, KS | 1 |
| Santosh, B | 1 |
| Klein, K | 1 |
| Sugathan, A | 1 |
| Nassery, N | 1 |
| Dombkowski, A | 1 |
| Zanger, UM | 1 |
| Waxman, DJ | 1 |
| Brunzell, JD | 3 |
| Zambon, A | 3 |
| Deeb, SS | 1 |
| Lian, J | 1 |
| Quiroga, AD | 1 |
| Li, L | 1 |
| Lehner, R | 1 |
| Tietjen, I | 2 |
| Singaraja, RR | 2 |
| Radomski, C | 1 |
| Barhdadi, A | 1 |
| McEwen, J | 2 |
| Chan, E | 1 |
| Mattice, M | 1 |
| Legendre, A | 1 |
| Franchini, PL | 1 |
| Dubé, MP | 2 |
| Hayden, MR | 2 |
| Sivapalaratnam, S | 1 |
| Hovingh, K | 1 |
| Castro-Perez, J | 1 |
| Collins, HL | 1 |
| Adelman, SJ | 1 |
| Riwanto, M | 1 |
| Manz, J | 1 |
| Hubbard, B | 1 |
| Wong, K | 1 |
| Mitnaul, LJ | 1 |
| van Heek, M | 1 |
| Lin, L | 1 |
| Roddy, TA | 1 |
| Dallinge-Thie, G | 1 |
| van Vark-van der Zee, L | 1 |
| Verwoert, G | 1 |
| Winther, M | 1 |
| van Duijn, C | 1 |
| Hofman, A | 1 |
| Trip, MD | 1 |
| Marais, AD | 1 |
| Asztalos, B | 1 |
| Sijbrands, E | 1 |
| Jansen, H | 5 |
| Verhoeven, AJ | 2 |
| Sijbrands, EJ | 2 |
| Berneis, KK | 1 |
| Krauss, RM | 2 |
| Su, ZG | 1 |
| Zhang, SZ | 1 |
| Hou, YP | 1 |
| Zhang, L | 1 |
| Huang, DJ | 1 |
| Liao, LC | 1 |
| Xiao, CY | 1 |
| Park, KW | 1 |
| Choi, JH | 1 |
| Chae, IH | 1 |
| Cho, HJ | 1 |
| Oh, S | 1 |
| Kim, HS | 1 |
| Lee, MM | 1 |
| Park, YB | 1 |
| Choi, YS | 1 |
| Hakala, JK | 1 |
| Oksjoki, R | 1 |
| Laine, P | 1 |
| Du, H | 2 |
| Grabowski, GA | 2 |
| Kovanen, PT | 1 |
| Pentikäinen, MO | 1 |
| Azumi, H | 1 |
| Kojima, Y | 1 |
| Rikitake, Y | 1 |
| Takeuchi, S | 1 |
| Inoue, N | 1 |
| Kawashima, S | 1 |
| Hayashi, Y | 1 |
| Itoh, H | 1 |
| Quertermous, T | 1 |
| Yokoyama, M | 1 |
| Camejo, G | 1 |
| Baroni, MG | 1 |
| Berni, A | 1 |
| Romeo, S | 1 |
| Arca, M | 1 |
| Tesorio, T | 1 |
| Sorropago, G | 1 |
| Di Mario, U | 1 |
| Galton, DJ | 2 |
| Buechler, C | 1 |
| Ullrich, H | 1 |
| Aslanidis, C | 1 |
| Bared, SM | 1 |
| Lingenhel, A | 1 |
| Ritter, M | 1 |
| Schmitz, G | 1 |
| MITCHELL, JR | 1 |
| BRONTE-STEWART, B | 1 |
| GOTTSEGEN, G | 1 |
| TOROK, E | 1 |
| NESTEL, PJ | 1 |
| SLACK, J | 1 |
| SEYMOUR, J | 1 |
| MCDONALD, L | 1 |
| LOVE, F | 1 |
| Bertocco, S | 1 |
| Vitturi, N | 1 |
| Polentarutti, V | 1 |
| Vianello, D | 1 |
| Crepaldi, G | 1 |
| Ng, MK | 1 |
| Quinn, CM | 1 |
| McCrohon, JA | 1 |
| Nakhla, S | 1 |
| Jessup, W | 1 |
| Handelsman, DJ | 1 |
| Celermajer, DS | 1 |
| Death, AK | 1 |
| Suzuki, S | 1 |
| Gejyo, F | 1 |
| Schiavi, S | 1 |
| Wan, N | 1 |
| Levine, M | 1 |
| Witte, DP | 1 |
| Ayyobi, AF | 2 |
| Wang, M | 1 |
| Briggs, MR | 1 |
| de Andrade, FM | 1 |
| Silveira, FR | 1 |
| Arsand, M | 1 |
| Antunes, AL | 1 |
| Torres, MR | 1 |
| Zago, AJ | 1 |
| Callegari-Jaques, SM | 1 |
| Hutz, MH | 1 |
| Foulkes, AS | 1 |
| Reilly, M | 1 |
| Zhou, L | 1 |
| Wolfe, M | 1 |
| Rader, DJ | 3 |
| Allen, A | 1 |
| Belton, C | 1 |
| Patterson, C | 1 |
| Horan, P | 1 |
| McGlinchey, P | 1 |
| Spence, M | 1 |
| Evans, A | 1 |
| Fogarty, D | 1 |
| McKeown, P | 1 |
| Hill, JS | 1 |
| Molhuizen, HO | 1 |
| Lear, SA | 1 |
| Badellino, KO | 2 |
| Wolfe, ML | 2 |
| Reilly, MP | 2 |
| Karackattu, SL | 1 |
| Trigatti, B | 1 |
| Krieger, M | 1 |
| Souverein, OW | 1 |
| Tanck, MW | 1 |
| Kuivenhoven, JA | 2 |
| Peters, RI | 1 |
| Schiffers, PM | 1 |
| van der Wall, EE | 1 |
| Doevendans, PA | 1 |
| Reitsma, PH | 1 |
| Zwinderman, AH | 2 |
| Jukema, JW | 2 |
| Takata, M | 1 |
| Inazu, A | 1 |
| Katsuda, S | 1 |
| Miwa, K | 1 |
| Kawashiri, MA | 1 |
| Nohara, A | 1 |
| Higashikata, T | 1 |
| Mabuchi, H | 1 |
| Yamagishi, M | 1 |
| Fan, YM | 1 |
| Rontu, R | 1 |
| Ilveskoski, E | 1 |
| Goebeler, S | 1 |
| Kajander, O | 1 |
| Mikkelsson, J | 1 |
| Viiri, LE | 1 |
| Perola, M | 1 |
| Karhunen, PJ | 1 |
| Volcik, K | 1 |
| Ballantyne, CM | 1 |
| Pownall, HJ | 1 |
| Sharrett, AR | 1 |
| Boerwinkle, E | 1 |
| Tang, NP | 1 |
| Wang, LS | 1 |
| Zhou, B | 1 |
| Gu, HJ | 1 |
| Sun, QM | 1 |
| Cong, RH | 1 |
| Zhu, HJ | 1 |
| Wang, B | 1 |
| Huang, L | 1 |
| Li, AM | 1 |
| Song, YM | 1 |
| Jin, J | 1 |
| Geng, ZH | 1 |
| Yu, XJ | 1 |
| Deng, MY | 1 |
| van Acker, BA | 1 |
| Botma, GJ | 1 |
| Boer, JM | 1 |
| Seidell, JC | 1 |
| Karpe, F | 2 |
| Steiner, G | 2 |
| Uffelman, K | 1 |
| Olivecrona, T | 2 |
| Hamsten, A | 2 |
| Tornvall, P | 1 |
| Carlson, LA | 1 |
| Dugi, KA | 2 |
| Feuerstein, IM | 1 |
| Hill, S | 1 |
| Shih, J | 1 |
| Santamarina-Fojo, S | 1 |
| Brewer, HB | 1 |
| Hoeg, JM | 1 |
| Saitoh, Y | 1 |
| Sich, D | 1 |
| Saïdi, Y | 1 |
| Giral, P | 1 |
| Egloff, M | 1 |
| Auer, C | 1 |
| Gautier, V | 1 |
| Turpin, G | 1 |
| Beucler, I | 1 |
| Hokanson, JE | 1 |
| Brown, BG | 1 |
| Allayee, H | 1 |
| Dominguez, KM | 1 |
| Aouizerat, BE | 1 |
| Rotter, JI | 1 |
| Lu, J | 1 |
| Cantor, RM | 1 |
| de Bruin, TW | 1 |
| Lusis, AJ | 1 |
| Moennig, G | 1 |
| Wiebusch, H | 1 |
| Enbergs, A | 1 |
| Dorszewski, A | 1 |
| Kerber, S | 1 |
| Schulte, H | 1 |
| Vielhauer, C | 1 |
| Haverkamp, W | 1 |
| Assmann, G | 1 |
| Breithardt, G | 1 |
| Funke, H | 1 |
| Gotto, AM | 1 |
| Ihaya, A | 1 |
| Muraoka, R | 1 |
| Chiba, Y | 1 |
| Uesaka, T | 1 |
| Morioka, K | 1 |
| Matsuyama, K | 1 |
| Tsuda, T | 1 |
| Nara, M | 1 |
| Niwa, H | 1 |
| Brandauer, K | 1 |
| Schmidt, N | 1 |
| Nau, B | 1 |
| Schneider, JG | 1 |
| Mentz, S | 1 |
| Keiper, T | 1 |
| Schaefer, JR | 1 |
| Meissner, C | 1 |
| Kather, H | 1 |
| Bahner, ML | 1 |
| Fiehn, W | 1 |
| Kreuzer, J | 1 |
| Wan, S | 1 |
| Arifi, AA | 1 |
| Chan, CS | 1 |
| Ng, CS | 1 |
| Wan, IY | 1 |
| Lee, TW | 1 |
| Yim, AP | 1 |
| Thorn, JA | 1 |
| Chamberlain, JC | 1 |
| Alcolado, JC | 1 |
| Oka, K | 1 |
| Chan, L | 1 |
| Stocks, J | 1 |
| Barth, JD | 2 |
| Kromhout, D | 2 |
| Reiber, JH | 2 |
| Birkenhäger, JC | 2 |
| Arntzenius, AC | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Subjects With Stable Coronary Heart Disease[NCT03351738] | Phase 2 | 133 participants (Actual) | Interventional | 2017-12-13 | Completed | ||
| Do Innovative Strategies Complement Medical Management to Reduce Cardiovascular Risk Factors Following Coronary Artery Bypass Graft Surgery?[NCT00462436] | Phase 2 | 35 participants (Anticipated) | Interventional | 2007-02-28 | Completed | ||
| The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes[NCT01384058] | Phase 4 | 41 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Inflammation and the Metabolic Syndrome in Humans[NCT00954824] | 50 participants (Actual) | Interventional | 2003-08-31 | Completed | |||
| Effects of Fatty Acid Composition Ratios of Oral Fatty Loads on the Dynamic Metabolism of Postprandial Lipid and Triglyceride-Rich Lipoproteins in Chinese NIDDM Out-Patients[NCT00467168] | Phase 1/Phase 2 | 30 participants | Interventional | 1998-01-31 | Completed | ||
| Bioavailability Assays of Oleanolic Acid, Formulated as Functional Olive Oil, in Healthy Subjects. Pharmacokinetic Analysis and Study of Its Integration in Postprandial Human Triglyceride-Rich Lipoproteins[NCT05529953] | 22 participants (Actual) | Interventional | 2021-03-15 | Completed | |||
| Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia[NCT00005313] | 450 participants (Actual) | Observational | 2001-04-30 | Completed | |||
| Familial Atherosclerosis Treatment Study[NCT00000512] | Phase 3 | 146 participants (Actual) | Interventional | 1984-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
AUC30d after the last dose of MEDI5884 is reported. (NCT03351738)
Timeframe: Day 61 (pre-dose), and on Days 64, 68, 71, and 91
| Intervention | μg⋅day/mL (Mean) |
|---|---|
| MEDI5884 50 mg | 14.6 |
| MEDI5884 100 mg | 51.8 |
| MEDI5884 200 mg | 191 |
| MEDI5884 350 mg | 584 |
| MEDI5884 500 mg | 1020 |
Maximum observed serum concentration (Cmax) of MEDI5884 after the last dose is reported. (NCT03351738)
Timeframe: Day 61 (pre-dose), and on Days 64, 68, 71, 91, 111, and 151
| Intervention | μg/mL (Mean) |
|---|---|
| MEDI5884 50 mg | 1.01 |
| MEDI5884 100 mg | 4.63 |
| MEDI5884 200 mg | 11.9 |
| MEDI5884 350 mg | 28.5 |
| MEDI5884 500 mg | 46.3 |
Number of participants with clinically important changes in ECGs from baseline are reported. Clinically important changes in ECGs is defined as any clinical significant difference in heart rate, RR interval, PR interval, QRS, and QT intervals from the primary lead of the digital 12-lead ECG from baseline. (NCT03351738)
Timeframe: Day 1 (Baseline) through Day 241
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| MEDI5884 50 mg | 0 |
| MEDI5884 100 mg | 0 |
| MEDI5884 200 mg | 0 |
| MEDI5884 350 mg | 0 |
| MEDI5884 500 mg | 0 |
Number of participants with clinically important changes in laboratory parameters from baseline are reported. Clinically important changes in laboratory parameters is defined as any clinical significant difference in analysis of serum chemistry, hematology, and urine from baseline. (NCT03351738)
Timeframe: Day 1 (Baseline) through Day 241
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| MEDI5884 50 mg | 0 |
| MEDI5884 100 mg | 0 |
| MEDI5884 200 mg | 0 |
| MEDI5884 350 mg | 0 |
| MEDI5884 500 mg | 0 |
Number of participants with clinically important changes in physical examinations from baseline are reported. Clinically important changes in physical examinations is defined as any clinical significant difference in general appearance, head, ears, eyes, nose, throat, neck, skin, heart, lung, abdomen, musculoskeletal system, endocrine system, nervous system, height, and weight from baseline. (NCT03351738)
Timeframe: Day 1 (Baseline) through Day 241
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| MEDI5884 50 mg | 0 |
| MEDI5884 100 mg | 0 |
| MEDI5884 200 mg | 0 |
| MEDI5884 350 mg | 0 |
| MEDI5884 500 mg | 0 |
Number of participants with clinically important changes in vital signs from baseline are reported. Vital signs measurements were obtained after the participant had rested in the supine position for at least 10 minutes at the recording time. Clinically important changes in vital signs from baseline is defined as any clinical significant difference in the vital sign parameters (blood pressure, heart rate, body temperature, and respiratory rate) from baseline. (NCT03351738)
Timeframe: Day 1 (Baseline) through Day 241
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| MEDI5884 50 mg | 0 |
| MEDI5884 100 mg | 0 |
| MEDI5884 200 mg | 0 |
| MEDI5884 350 mg | 0 |
| MEDI5884 500 mg | 0 |
Treatment-emergent ADA is defined as the sum of treatment-induced ADA (post baseline-positive only) and treatment-boosted ADA (baseline ADA titer that was boosted to a 4-fold or higher level following drug administration). (NCT03351738)
Timeframe: Day 1 (pre-dose), on Day 8, Day 31 (pre-dose), Day 61 (pre-dose), on Days 151 and 241
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 1 |
| MEDI5884 50 mg | 1 |
| MEDI5884 100 mg | 1 |
| MEDI5884 200 mg | 3 |
| MEDI5884 350 mg | 3 |
| MEDI5884 500 mg | 3 |
Terminal half-life is the time required for the plasma concentration to fall by 50% during the terminal phase. The t½ of MEDI5884 after the last dose is reported. (NCT03351738)
Timeframe: Day 61 (pre-dose), and on Days 64, 68, 71, 91, 111, and 151
| Intervention | Days (Mean) |
|---|---|
| MEDI5884 100 mg | 7.56 |
| MEDI5884 200 mg | 8.09 |
| MEDI5884 350 mg | 10.3 |
| MEDI5884 500 mg | 13.7 |
Change from baseline in apolipoprotein B is reported. (NCT03351738)
Timeframe: Day 1 (Baseline), and Days 31, 61, and 91
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Day 31 | Day 61 | Day 91 | |
| MEDI5884 100 mg | 5.1 | 3.5 | 2.3 |
| MEDI5884 200 mg | 2.2 | 2.6 | 2.0 |
| MEDI5884 350 mg | 7.1 | 3.7 | 2.9 |
| MEDI5884 50 mg | 0.5 | -1.2 | 3.6 |
| MEDI5884 500 mg | 7.1 | 6.2 | 7.8 |
| Placebo | 3.3 | 1.2 | -0.5 |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. (NCT03351738)
Timeframe: Day 1 (Baseline) through Day 241
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAEs | TESAEs | |
| MEDI5884 100 mg | 11 | 1 |
| MEDI5884 200 mg | 12 | 0 |
| MEDI5884 350 mg | 13 | 4 |
| MEDI5884 50 mg | 10 | 2 |
| MEDI5884 500 mg | 13 | 0 |
| Placebo | 17 | 2 |
Percent change from baseline in HDL-C is reported. (NCT03351738)
Timeframe: Day 1 (Baseline), and Days 31, 61, and 91
| Intervention | Percent change (Mean) | ||
|---|---|---|---|
| Day 31 | Day 61 | Day 91 | |
| MEDI5884 100 mg | 22.95 | 28.28 | 21.82 |
| MEDI5884 200 mg | 27.25 | 37.65 | 35.63 |
| MEDI5884 350 mg | 44.12 | 39.74 | 43.29 |
| MEDI5884 50 mg | 7.37 | 4.58 | 1.98 |
| MEDI5884 500 mg | 55.80 | 49.58 | 48.31 |
| Placebo | -3.08 | -4.69 | -3.62 |
(NCT00954824)
Timeframe: 24 hours
| Intervention | ng/mL (Mean) |
|---|---|
| Endotoxin (LPS) | 507 |
14 reviews available for 1-anilino-8-naphthalenesulfonate and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Genome-wide meta-analysis of phytosterols reveals five novel loci and a detrimental effect on coronary atherosclerosis.
Topics: ABO Blood-Group System; Adult; Apolipoproteins E; ATP Binding Cassette Transporter, Subfamily G, Mem | 2022 |
Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the "Prime Time" of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?
Topics: Adipose Tissue; Angiopoietin-Like Protein 4; Animals; Coronary Artery Disease; Coronary Disease; Hum | 2021 |
Gene polymorphism associated with angiotensinogen (M235T), endothelial lipase (584C/T) and susceptibility to coronary artery disease: a meta-analysis.
Topics: Alleles; Angiotensinogen; Asian People; Case-Control Studies; Coronary Artery Disease; Genetic Predi | 2020 |
Significant association between the endothelial lipase gene 584C/T polymorphism and coronary artery disease risk.
Topics: Coronary Artery Disease; Humans; Incidence; Lipase; Mutation; Polymorphism, Restriction Fragment Len | 2020 |
Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Topics: Acyltransferases; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dysli | 2021 |
NAFLD-NASH: An Under-Recognized Epidemic.
Topics: Coronary Artery Disease; Epidemics; Female; Genetic Predisposition to Disease; Global Health; Hispan | 2018 |
A novel mutation in PNPLA2 causes neutral lipid storage disease with myopathy and triglyceride deposit cardiomyovasculopathy: a case report and literature review.
Topics: Cardiomyopathies; Coronary Angiography; Coronary Artery Disease; Genotyping Techniques; Humans; Lipa | 2014 |
The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype.
Topics: Animals; Coronary Artery Disease; Genome-Wide Association Study; Humans; Hypercholesterolemia; Hyper | 2012 |
Hepatic lipase: a pro- or anti-atherogenic protein?
Topics: Animals; Biological Transport; Carbohydrate Metabolism; Coronary Artery Disease; Coronary Vessels; D | 2002 |
Metabolic origins and clinical significance of LDL heterogeneity.
Topics: Coronary Artery Disease; Disease Susceptibility; Humans; Lipase; Lipoproteins, LDL; Phenotype | 2002 |
Metabolic origins and clinical significance of LDL heterogeneity.
Topics: Coronary Artery Disease; Disease Susceptibility; Humans; Lipase; Lipoproteins, LDL; Phenotype | 2002 |
Metabolic origins and clinical significance of LDL heterogeneity.
Topics: Coronary Artery Disease; Disease Susceptibility; Humans; Lipase; Lipoproteins, LDL; Phenotype | 2002 |
Metabolic origins and clinical significance of LDL heterogeneity.
Topics: Coronary Artery Disease; Disease Susceptibility; Humans; Lipase; Lipoproteins, LDL; Phenotype | 2002 |
Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins.
Topics: Animals; Arteriosclerosis; Cholesterol; Coronary Artery Disease; Humans; Ligands; Lipase; Lipoprotei | 2003 |
Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hype | 2003 |
HDL: the metabolism, function, and therapeutic importance.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; ATP-Binding Cassette Transporters; Carrier Pr | 2004 |
[Hepatic triglyceride lipase deficiency, hepatic lipase deficiency].
Topics: Animals; Coronary Artery Disease; Diagnosis, Differential; Humans; Hyperlipidemias; Lipase; Liver; P | 1998 |
6 trials available for 1-anilino-8-naphthalenesulfonate and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease.
Topics: Aged; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relatio | 2021 |
[Effects of lipid-modulation and antiplatelet treatment on the endothelial lipase expression].
Topics: Adult; Aged; Blood Platelets; Coronary Artery Disease; Female; Humans; Hypolipidemic Agents; Lipase; | 2010 |
High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants.
Topics: Aged; Case-Control Studies; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery D | 2008 |
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Centrifugation, Density Gradient; Chemical Phenom | 1999 |
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Centrifugation, Density Gradient; Chemical Phenom | 1999 |
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Centrifugation, Density Gradient; Chemical Phenom | 1999 |
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Centrifugation, Density Gradient; Chemical Phenom | 1999 |
Detection of missense mutations in the genes for lipoprotein lipase and hepatic triglyceride lipase in patients with dyslipidemia undergoing coronary angiography.
Topics: Adult; Aged; Alleles; Base Sequence; Coronary Angiography; Coronary Artery Disease; DNA; Gene Freque | 2000 |
Hyperamylasemia and subclinical pancreatitis after cardiac surgery.
Topics: Adult; Aged; Amylases; Aortic Valve; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Artery | 2001 |
68 other studies available for 1-anilino-8-naphthalenesulfonate and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Multivessel Coronary Artery Disease Complicated by Diabetes Mellitus Has a Relatively Small Effect on Endothelial and Lipoprotein Lipases Expression in the Human Atrial Myocardium and Coronary Perivascular Adipose Tissue.
Topics: Atrial Fibrillation; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Heart Atria; Huma | 2023 |
The Gene and Protein Expression of the Main Components of the Lipolytic System in Human Myocardium and Heart Perivascular Adipose Tissue. Effect of Coronary Atherosclerosis.
Topics: Adipose Tissue; Cell Cycle Proteins; Coronary Artery Disease; Gene Expression; Heart; Humans; Lipase | 2020 |
A study of associations between CUBN, HNF1A, and LIPC gene polymorphisms and coronary artery disease.
Topics: Case-Control Studies; Coronary Artery Disease; Exome Sequencing; Female; Gene Frequency; Genetic Mar | 2020 |
Association between
Topics: Case-Control Studies; Coronary Artery Disease; Female; Humans; Iran; Lipase; Male; Middle Aged; Nitr | 2021 |
Roles of endothelial lipase gene related single nucleotide polymorphisms in patients with coronary artery disease.
Topics: Aged; Apolipoprotein A-I; Case-Control Studies; China; Cholesterol, HDL; Coronary Artery Disease; Fe | 2021 |
The role of plasma lipoprotein lipase, hepatic lipase and GPIHBP1 in the metabolism of remnant lipoproteins and small dense LDL in patients with coronary artery disease.
Topics: Aged; Cholesterol, LDL; Coronary Artery Disease; Female; Humans; Lipase; Lipoproteins; Liver; Male; | 2018 |
LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study.
Topics: Aged; Cholesterol, LDL; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genome-W | 2019 |
Association of 584C/T polymorphism in endothelial lipase gene with risk of coronary artery disease.
Topics: Adult; Aged; Alleles; Case-Control Studies; Coronary Artery Disease; Female; Gene Frequency; Genetic | 2019 |
Association of hepatic lipase -514T allele with coronary artery disease and ankle-brachial index, dependence on the lipoprotein phenotype: the GENES study.
Topics: Aged; Alleles; Ankle Brachial Index; Case-Control Studies; Coronary Artery Disease; Genetic Predispo | 2013 |
A novel type of human spontaneous coronary atherosclerosis with triglyceride deposition.
Topics: Adult; Coronary Artery Disease; Foam Cells; Humans; Lipase; Male; Myocardial Ischemia; Triglycerides | 2014 |
Plasma activity of endothelial lipase impacts high-density lipoprotein metabolism and coronary risk factors in humans.
Topics: Adult; Aged; Aged, 80 and over; Animals; Chlorocebus aethiops; Coronary Artery Disease; COS Cells; F | 2014 |
Epipolymorphisms within lipoprotein genes contribute independently to plasma lipid levels in familial hypercholesterolemia.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; C | 2014 |
Lack of association between a common polymorphism of the endothelial lipase gene and early-onset coronary artery disease in a Chinese Han population.
Topics: Asian People; Case-Control Studies; Coronary Artery Disease; Cytosine; Female; Gene Frequency; Genet | 2014 |
Association of endothelial lipase gene-384A/C with coronary artery disease in Han Chinese people.
Topics: Case-Control Studies; China; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Diseas | 2015 |
Specific enrichment of 2-arachidonoyl-lysophosphatidylcholine in carotid atheroma plaque from type 2 diabetic patients.
Topics: Aged; Arachidonic Acid; Cholesterol; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Typ | 2016 |
Cardiovascular risk factor control is insufficient in young patients with coronary artery disease.
Topics: Adult; Age of Onset; Antihypertensive Agents; Biomarkers; Blood Pressure; Body Mass Index; Cholester | 2016 |
Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Di | 2016 |
Associations of Rs3744841 and Rs3744843 Polymorphisms in Endothelial Lipase Gene with Risk of Coronary Artery Disease and Lipid Levels in a Chinese Population.
Topics: Alleles; Asian People; Case-Control Studies; Coronary Angiography; Coronary Artery Disease; Female; | 2016 |
Association of the I148M/PNPLA3 (rs738409) polymorphism with premature coronary artery disease, fatty liver, and insulin resistance in type 2 diabetic patients and healthy controls. The GEA study.
Topics: Adult; Alanine Transaminase; Calcinosis; Case-Control Studies; Coronary Artery Disease; Diabetes Mel | 2017 |
Endothelial lipase plasma levels are increased in both sexes in stable coronary artery disease and only in women with acute coronary syndrome but not associated with the severity of coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Coronary Artery Disease; Croatia; Cross-Sectional Studies; Female; Hu | 2016 |
PNPLA3, TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease.
Topics: Acyltransferases; Case-Control Studies; Coronary Artery Disease; Databases, Genetic; Gene Frequency; | 2017 |
Combined hepatic lipase -514C/T and cholesteryl ester transfer protein I405V polymorphisms are associated with the risk of coronary artery disease.
Topics: Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Female; Genetic Predisposition to Dise | 2009 |
The genetics of high-density lipoprotein metabolism: clinical relevance for therapeutic approaches.
Topics: Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholester | 2009 |
Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT.
Topics: Aged; Alleles; Cholesterol, HDL; Coronary Artery Disease; Female; Genetic Variation; Genotype; Human | 2010 |
Smaller low-density lipoprotein size as a possible risk factor for the prevalence of coronary artery diseases in haemodialysis patients: associations of cholesteryl ester transfer protein and the hepatic lipase gene polymorphism with low-density lipoprote
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Chi-Square Distribution; Cholesterol Ester Tra | 2011 |
Relationship of APOA5, PPARγ and HL gene variants with serial changes in childhood body mass index and coronary artery disease risk factors in young adulthood.
Topics: Apolipoprotein A-V; Apolipoproteins A; Body Mass Index; Child; Cohort Studies; Coronary Artery Disea | 2011 |
Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease.
Topics: Adult; Aged; Animals; Apolipoprotein A-V; Apolipoproteins A; ATP Binding Cassette Transporter 1; ATP | 2011 |
Ces3/TGH deficiency improves dyslipidemia and reduces atherosclerosis in Ldlr(-/-) mice.
Topics: Animals; Aorta; Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, V | 2012 |
Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol.
Topics: Aged; Alternative Splicing; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; C | 2012 |
The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans.
Topics: Cholesterol, HDL; Cohort Studies; Coronary Artery Disease; Heterozygote; Humans; Lipase; Mutation, M | 2013 |
Relationship between a novel polymorphism of hepatic lipase gene and coronary artery disease.
Topics: Alleles; Apolipoproteins; Base Sequence; Case-Control Studies; China; Chromatography, High Pressure | 2002 |
Hepatic lipase C514T polymorphism and its relationship with plasma HDL-C levels and coronary artery disease in Koreans.
Topics: Cholesterol, HDL; Coronary Artery Disease; Demography; Female; Gene Frequency; Genotype; Humans; Kor | 2003 |
Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions.
Topics: Apolipoprotein B-100; Apolipoproteins B; Cathepsin D; Coronary Artery Disease; Coronary Vessels; Foa | 2003 |
Immunohistochemical localization of endothelial cell-derived lipase in atherosclerotic human coronary arteries.
Topics: Aged; Aged, 80 and over; Cells, Cultured; Coronary Artery Disease; Coronary Vessels; Humans; Immunoh | 2003 |
Hydrolytic enzymes released from resident macrophages and located in the intima extracellular matrix as agents that modify retained apolipoprotein B lipoproteins.
Topics: Apolipoproteins B; Cathepsin D; Cells, Cultured; Coronary Artery Disease; Coronary Vessels; Extracel | 2003 |
Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD.
Topics: Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins B; Apolipoproteins C; Apo | 2003 |
Lipoprotein (a) downregulates lysosomal acid lipase and induces interleukin-6 in human blood monocytes.
Topics: Cells, Cultured; Coronary Artery Disease; Down-Regulation; Gene Expression Regulation, Enzymologic; | 2003 |
Alimentary lipaemia and haparin clearing in ischaemic heart-disease.
Topics: Coronary Artery Disease; Heart Diseases; Humans; Hyperlipidemias; Lipase; Lipids | 1959 |
[Studies on the treatment of circulatory diseases. II. Administration of vasolastine in coronary sclerosis].
Topics: Cardiovascular Diseases; Coronary Artery Disease; Coronary Disease; Enzyme Therapy; Enzymes; Humans; | 1960 |
Observations on heparin-induced clearing activity in ischaemic heart disease and the effect of prolonged heparin therapy.
Topics: Coronary Artery Disease; Coronary Disease; Heparin; Humans; Lipase; Lipid Metabolism; Lipids; Lipopr | 1961 |
LIPOPROTEIN-LIPASE LEVELS AND PLATELET STICKINESS IN PATIENTS WITH ISCHAEMIC HEART-DISEASE AND IN CONTROLS, DISTINGUISHING THOSE WITH AN AFFECTED FIRST-DEGREE RELATIVE.
Topics: Blood Coagulation Disorders; Blood Platelets; Clinical Enzyme Tests; Coronary Artery Disease; Corona | 1964 |
Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis.
Topics: Adult; Coronary Artery Disease; Dihydrotestosterone; DNA Primers; DNA, Complementary; Female; Humans | 2003 |
Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels.
Topics: Aged; Aged, 80 and over; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Co | 2003 |
Reduction of atherosclerotic plaques by lysosomal acid lipase supplementation.
Topics: Animals; Aortic Diseases; Aortic Valve; Arteriosclerosis; Cholesterol Esters; Coronary Artery Diseas | 2004 |
Association between -250G/A polymorphism of the hepatic lipase gene promoter and coronary artery disease and HDL-C levels in a Southern Brazilian population.
Topics: Adult; Brazil; Case-Control Studies; Cholesterol, HDL; Coronary Artery Disease; Female; Gene Frequen | 2004 |
Mixed modelling to characterize genotype-phenotype associations.
Topics: Adult; Aged; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genotype; Humans; L | 2005 |
Family-based association studies of lipid gene polymorphisms in coronary artery disease.
Topics: Adult; Age of Onset; Coronary Artery Disease; Female; Genetic Markers; Genetic Predisposition to Dis | 2005 |
Cholesterol ester transfer protein (CETP) Taq1B polymorphism influences the effect of a standardized cardiac rehabilitation program on lipid risk markers.
Topics: Apolipoproteins E; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; F | 2005 |
Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis.
Topics: Adult; Aged; Anticoagulants; Cholesterol, HDL; Coronary Artery Disease; Cross-Sectional Studies; Enz | 2006 |
Hepatic lipase deficiency delays atherosclerosis, myocardial infarction, and cardiac dysfunction and extends lifespan in SR-BI/apolipoprotein E double knockout mice.
Topics: Age of Onset; Animals; Aorta; Apolipoproteins E; Cardiomegaly; Coronary Artery Disease; Coronary Ves | 2006 |
Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels.
Topics: Alleles; Apolipoprotein A-I; Apolipoproteins E; ATP Binding Cassette Transporter 1; ATP-Binding Cass | 2006 |
CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Diseas | 2006 |
The hepatic lipase gene C-480T polymorphism in the development of early coronary atherosclerosis: the Helsinki Sudden Death Study.
Topics: Adult; Aged; Autopsy; Coronary Artery Disease; Death, Sudden; Humans; Lipase; Male; Middle Aged; Pol | 2007 |
Interaction effects of high-density lipoprotein metabolism gene variation and alcohol consumption on coronary heart disease risk: the atherosclerosis risk in communities study.
Topics: Age Factors; Alcohol Drinking; Aryldialkylphosphatase; Black People; Cholesterol Ester Transfer Prot | 2007 |
Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population.
Topics: Amino Acid Substitution; Case-Control Studies; China; Coronary Artery Disease; Female; Genetic Predi | 2008 |
[Significance of the ratio of circulating endothelial cell expressing endothelial lipase and supersensitivity C-reactive protein in prognosis of patients with coronary artery disease].
Topics: C-Reactive Protein; Coronary Artery Disease; Endothelial Cells; Female; Follow-Up Studies; Humans; L | 2007 |
Endothelial lipase is increased in vivo by inflammation in humans.
Topics: Adiponectin; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Endothelium, Vascular; Female; | 2008 |
Postprandial lipoproteins and progression of coronary atherosclerosis.
Topics: Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Apolipoproteins E; Chylomicrons; Coron | 1994 |
Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Dietary Fats; Glycop | 1993 |
Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Dietary Fats; Glycop | 1993 |
Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Dietary Fats; Glycop | 1993 |
Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Dietary Fats; Glycop | 1993 |
Lipoprotein lipase correlates positively and hepatic lipase inversely with calcific atherosclerosis in homozygous familial hypercholesterolemia.
Topics: Achilles Tendon; Adolescent; Adult; Calcinosis; Child; Child, Preschool; Coronary Artery Disease; Fe | 1997 |
Hyperalphalipoproteinemia: characterization of a cardioprotective profile associating increased high-density lipoprotein2 levels and decreased hepatic lipase activity.
Topics: Adult; Aged; Carotid Stenosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Arter | 1998 |
Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia.
Topics: Adult; Cholesterol, HDL; Coronary Artery Disease; Female; Genetic Linkage; Humans; Hyperlipidemia, F | 2000 |
Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report.
Topics: Animals; Carrier Proteins; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Cohort Studies; | 2001 |
Low hepatic lipase activity is a novel risk factor for coronary artery disease.
Topics: Adult; Alleles; Coronary Artery Disease; Coronary Vessels; Humans; Lipase; Liver; Male; Polymorphism | 2001 |
Is hyperamylasemia after cardiac surgery due to cardiopulmonary bypass?
Topics: Aged; Amylases; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Artery Disease; Creatinine; | 2002 |
Lipoprotein and hepatic lipase gene variants in coronary atherosclerosis.
Topics: Alleles; Coronary Artery Disease; Genetic Markers; Genotype; Humans; Lipase; Lipoprotein Lipase; Liv | 1990 |
Diet and the role of lipoproteins, lipases, and thyroid hormones in coronary lesion growth.
Topics: Adult; Coronary Angiography; Coronary Artery Disease; Dietary Fats; Humans; Image Processing, Comput | 1987 |
Progression and regression of human coronary atherosclerosis. The role of lipoproteins, lipases and thyroid hormones in coronary lesion growth.
Topics: Angiocardiography; Cholesterol, HDL; Coronary Artery Disease; Humans; Lipase; Lipoproteins; Male; Mi | 1987 |